Methods to introduce targeted double-strand breaks (DSBs) into DNA enable precise genome editing by increasing the rate at which externally supplied DNA fragments are incorporated into the genome through homologous recombination. The efficiency of these methods is limited by nonhomologous end joining (NHEJ), an alternative DNA repair pathway that competes with homology-directed repair (HDR). To promote HDR at the expense of NHEJ, we targeted DNA ligase IV, a key enzyme in the NHEJ pathway, using the inhibitor Scr7. Scr7 treatment increased the efficiency of HDR-mediated genome editing, using Cas9 in mammalian cell lines and in mice for all four genes examined, up to 19-fold. This approach should be applicable to other customizable endonucleases, such as zinc finger nucleases and transcription activatorlike effector nucleases, and to nonmammalian cells with sufficiently conserved mechanisms of NHEJ and HDR.
l e t t e r s
Methods to introduce targeted double-strand breaks (DSBs) into DNA enable precise genome editing by increasing the rate at which externally supplied DNA fragments are incorporated into the genome through homologous recombination. The efficiency of these methods is limited by nonhomologous end joining (NHEJ), an alternative DNA repair pathway that competes with homology-directed repair (HDR). To promote HDR at the expense of NHEJ, we targeted DNA ligase IV, a key enzyme in the NHEJ pathway, using the inhibitor Scr7. Scr7 treatment increased the efficiency of HDR-mediated genome editing, using Cas9 in mammalian cell lines and in mice for all four genes examined, up to 19-fold. This approach should be applicable to other customizable endonucleases, such as zinc finger nucleases and transcription activatorlike effector nucleases, and to nonmammalian cells with sufficiently conserved mechanisms of NHEJ and HDR.
The type II bacterial clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system is an efficient tool for the targeted introduction of mutations into eukaryotic genomes 1, 2 . Properly designed single guide (sg) RNAs efficiently induce Cas9-mediated DSBs at desired target sites while minimizing off-target effects 3, 4 . The DSBs stimulate DNA repair by at least two distinct mechanisms-NHEJ and HDR-both of which are active in nearly all cell types and organisms 2 . Cas9-mediated modification of the murine genome through NHEJ can reach efficiencies of 20-60% 5, 6 . Because NHEJ is error-prone and introduces unpredictable patterns of insertions and deletions (indels) [6] [7] [8] , it is suitable for introducing small random mutations. However, it does not enable precise genome editing by HDR-mediated incorporation of an exogenous DNA fragment. This has been achieved by co-injection of a targeted endonuclease and a single-stranded or double-stranded DNA template homologous to the sequences flanking the cleavage site 5, 6, 9 . Because the frequency of HDR is inherently low 5, 6, 9 , the efficiency of insertional mutagenesis using this strategy is only 0.5-20% 5, 6, 9 . This poses a challenge for many applications, such as generating sufficient numbers of genome-edited animals.
HDR is less frequent than NHEJ and occurs only during S and G2 phase 5, 6, 9 , whereas NHEJ occurs throughout the cell cycle 10 . HDR occurs not sequentially but rather concurrently with NHEJ and occurs more frequently in NHEJ-deficient cells, for example, Ku70-, XRCC4-and DNA-PKcs-deficient cells 11 . We hypothesized that inhibition of NHEJ should improve the frequency of HDR. NHEJ is a broad term comprising two types of pathways: ligase IV-dependent NHEJ (so-called canonical NHEJ (C-NHEJ)), which mainly functions in end-joining, and the alternative NHEJ (alt-NHEJ/A-NHEJ/A-EJ) pathways, which require DNA ligase I/III and are induced by C-NHEJ pathway deficiencies 12 . In most cases, DNA repair after DSBs is mediated by the C-NHEJ pathway 13 . We thus focused on DNA ligase IV, a key enzyme for C-NHEJ, as a potential target to improve HDR efficiency. Indeed, the frequency of HDR stimulated by zinc finger nucleases is increased in Drosophila melanogaster strains lacking ligase IV 14 . Homologous recombination is promoted in ligase IV-deficient NALM6 cells 15 . However, deletion of DNA ligase IV in mice causes late-stage embryo lethality 16 , preventing the use of zygotes genetically deficient in DNA ligase IV as a strategy for making mutant mice.
To transiently target DNA ligase IV, we used a DNA ligase IV inhibitor, Scr7, initially identified as an anti-cancer agent 17 . Scr7 targets the DNA binding domain of DNA ligase IV, reducing its affinity for DSBs and inhibiting its function 17 . Scr7 also inhibits DNA ligase III (but not DNA ligase I), albeit less efficiently 17 . Treatment of mice with Scr7 affects lymphocyte development, as DNA ligase IV plays a key role in the joining of coding ends during V(D)J recombination by means of C-NHEJ 16 . The defects in lymphocyte development upon Scr7 treatment are transient and reversible, due to the noncovalent mode of binding of Scr7 (ref. 17) . We hypothesized that co-injection of CRISPR-Cas9 constructs with Scr7 into fertilized zygotes would allow mouse embryos to progress through development normally and show improved efficiency in obtaining defined DNA insertions. Accordingly, we used Scr7 to enhance the frequency of HDR by transiently blocking NHEJ (with the exception of DNA ligase I-dependent alt-NHEJ), resulting in precise genome editing by CRISPR-Cas9 in both cultured cells and in mice.
To investigate whether Scr7 improves the insertion efficiency of short DNA fragments at a given locus, we first tested whether Scr7 treatment enhances the rate of HDR in cultured human cell lines (Fig. 1) . We generated epithelial (A549) and melanoma (MelJuSo) cell line derivatives expressing Cas9 and the TSG101 sgRNA, which targets exon 8 of the tumor susceptibility gene 101 (ref. 18) , under the control of a doxycycline-inducible promoter (Fig. 1a and l e t t e r s Supplementary Fig. 1a,b) . The targeting template comprises the intended insert (stop cassette) sandwiched between 100 base pair (bp) arms homologous to the sequence flanking the DSBs (Fig. 1a) . In the targeting template, one adenine and two guanines in the guide sequence, in addition to the PAM motif, were deleted to avoid DSBs on the plasmid donor (Fig. 1a, targeting template) . After 24 h of plasmid donor transfection, cells were treated with doxycycline to induce Cas9 expression, and with various concentrations of Scr7, for 24 h. The cells were then washed and incubated for an additional 24 h in fresh media. We chose a range of 0-1 µM Scr7 to maintain cells capable of entering S/G2 phase, which is necessary for HDR ( Supplementary  Fig. 2a-c) . For the A549 cells, which are relatively sensitive to Scr7, the efficiency of insertion at the target site in the presence of 0.01 µM Scr7 was improved about threefold relative to the untreated control. Efficiency was lower at higher concentrations of Scr7 (0.1-1 µM), but HDR frequencies at these concentrations were still higher than those in the untreated cells (Fig. 1b,c, the A549 lanes) . Similarly, the insertion efficiency was also enhanced in Scr7-treated MelJuSo cells in a dose-dependent manner up to 19-fold (Fig. 1c , the lanes labeled MelJuSo). To confirm whether precise insertion indeed increased upon Scr7 treatment, we performed both chip-based capillary electrophoresis and deep sequencing experiments ( Supplementary Fig. 3a-e) . Scr7 treatment increased both the frequency of all insertions, including imprecise insertions (Supplementary Fig. 3b ,e, 'insertion') and precise insertions, which rose 0.02-2.8% in MelJuSo cells upon treatment with 1 µM Scr7 (Supplementary Fig. 3e , 'precise insertion').
To assess the effect of Scr7 on insertion of longer DNA fragments, we also generated a Cas9-inducible murine bone marrow-derived dendritic cell line (DC2.4 cells) stably expressing an sgRNA that targeted the Tap1 (transporter, ATP-binding cassette, major histocompatibility complex 1) 19 locus at exon 1, and inserted the Venus fluorescent gene using pDonor0.2 (Fig. 1d, and Supplementary Fig. 1c npg l e t t e r s slightly toxic even at concentrations >10 µM (Supplementary Fig. 2d ), the DC2.4 cells were treated with 1 µM of Scr7. After treatment, we performed genotyping using two Venus-specific primer sets (no. 2 and no. 3), in addition to an external primer set (no. 1) (Fig. 1d) . Scr7 treatment improved the efficiency of insertion at the target site ~13-fold. The fold change of inserted alleles amplified by the Venusspecific internal primer sets no. 2 and no. 3 was similar to that using the primer set no. 1 (Fig. 1d, Given the increase in HDR frequency in cell lines exposed to Scr7, we next tested whether Scr7 would improve precise genome editing in mouse zygotes. First, we determined a baseline efficiency of deletion and insertion mutagenesis in zygotes when targeting multiple genes in the absence of Scr7. These included Os9 (osteosarcoma amplified 9, three types of sgRNAs) 20 and Lrrc8d (leucine-rich repeat containing 8 family, member D) 21 as targets of NHEJ-mediated deletion mutagenesis; and Msln (mesothelin 22 ) and Ighg3 (immunoglobulin heavy constant gamma 3; ref. 23) as targets for insertional mutagenesis through HDR. CRISPR-Cas9 constructs were microinjected into the cytoplasm of fertilized zygotes. Manipulated embryos were cultured to the two-cell stage and transferred into pseudopregnant females. The tails of pups carried to term were harvested for genotyping. Supplementary Table 1 shows the ratio of insertion-and/or deletion-mutated alleles for each gene over the total number of alleles present in the embryos obtained. The frequencies of NHEJ and HDR were calculated as the ratio of deletion and insertion alleles relative to wild-type alleles (Supplementary Table 1 ). We confirmed that deletional mutagenesis consistently occurred at ~20-60%, as previously reported (OS9: deletion sgRNAno. 1 = 28.6%; deletion sgRNAno. 2 = 45.8%; deletion sgRNAno. 3 = 20.0%, LRRC8D: deletion = 66.7%) 6 . The efficiency of insertional npg l e t t e r s mutagenesis in the same experiment was lower than that of deletional mutagenesis (Msln: deletion = 19.4%; insertion = 11.1%; IgG3 (also known as Ighg3): deletion = 44.4%; insertion = 16.7%), again confirming previous reports 5, 6 (Supplementary Table 1) .
We had previously generated Kell-LPETG mice by the introduction of a linker and an in-frame sortase recognition motif (LPETG) at the C terminus of the type II membrane protein Kell 24 . To examine whether treatment with Scr7 enhances the efficiency of HDRmediated insertional mutagenesis in mice, we therefore chose Kell as a target. As a second target, we introduced the LPETG sortase motif at the 3′ end of the immunoglobulin kappa constant region. We designed sgRNAs targeting the last exon of Kell and the last exon of the immunoglobulin kappa (Igκ) constant region (Igkc) as well as single-stranded DNA (ssDNA) oligonucleotides (targeting template) to introduce the desired insertion in close proximity to the DSBs (Fig. 2a) . Zygotes co-injected with CRISPR-Cas9 components (sgRNA, Cas9 mRNA and targeting template) and 1mM Scr7 developed normally to the blastocyst stage with an ~80% survival rate, comparable to the condition without Scr7 (Fig. 2b and Supplementary Fig. 5a-c) . The genotype of each blastocyst was then analyzed by PCR using an LPETG-specific primer. The insertion efficiency with Scr7 coinjection was significantly higher (P = 0.0012) compared to blastocysts not injected with Scr7 ( Fig. 2c and Table 1 ). Zygotes co-injected with Scr7 were also cultured to either the two-cell or blastocyst stage and then transferred into pseudo-pregnant mice (Fig. 2b) . DNA from the resulting E10 embryos was analyzed by digestion with MboI, by direct sequencing and by PCR with an LPETG-specific primer set (Fig. 2d-f and Table 1 ). For the Kell locus, we detected both NHEJmediated deletion alleles ( Fig. 2d and Supplementary Fig. 5d ) and LPETG-inserted alleles (Fig. 2d) in the absence of Scr7. In the presence of Scr7, only LPETG-insertion alleles were observed ( Fig. 2d and Table 1 ). After comparing the number of wild-type, deletion and insertion alleles, we found the insertion efficiency in Scr7-co-injected E10 embryos to be significantly enhanced compared to E10 embryos not injected with Scr7 (P = 0.003). We observed a similar effect of coinjection with Scr7 on the insertion efficiency of an LPETG-encoding DNA fragment into the Igkc locus (Fig. 2e,f, Supplementary Fig. 5e and Table 1 ), suggesting that improvements in insertion efficiency upon inhibition of NHEJ are not limited to a particular locus.
Inclusion of the DNA ligase IV inhibitor, Scr7, improved insertion efficiency of both short and long DNA fragments at the TSG101 and Tap1 target loci, respectively (Fig. 1) . In A549 cells, the use of higher concentrations of Scr7 attenuated HDR. This likely reflects cell type-dependent toxicity of Scr7 (Supplementary Fig. 2) . Co-injection of zygotes with Scr7 significantly improved the efficiency of HDRmediated insertional mutagenesis (Fig. 2c, P = 0.0012) . Modification of the Kell and the Igkc loci in the presence of Scr7 yielded embryos with the desired LPETG sequence, but no deletion-mutant embryos (Fig. 2d,f and Table 1 ). Because total indel frequency did not change in either example (Supplementary Fig. 3b,e) , increased efficiency of insertions upon treatment with Scr7 correlates with a decrease in deletions (Supplementary Fig. 3b,e) . Scr7 thus promotes the frequency of HDR through inhibition of NHEJ and favors precise insertions over random deletions.
As inhibition of NHEJ can induce apoptosis 17 , we considered the possibility that co-injection of Scr7 into zygotes reduces the number of deletion mutants without affecting the efficiency of insertional mutagenesis. However, treatment with Scr7 affected neither the viability of the injected zygotes nor the number of live pups born from Scr7-injected embryos (Supplementary Fig. 5 ). We also addressed the possibility that Scr7 had a detrimental effect on mouse generation, for example, by failure of germline transmission and/or increase of off-target effects. The offspring of Scr7-generated pups carried the same desired mutation as that of the parental mice, suggesting successful germline transmission (Supplementary Fig. 6 ) without off-target effects as evaluated by direct sequencing analysis (Supplementary Fig. 7) .
It is also possible that ligase IV deficiency may induce alternative NHEJ pathways, which produce longer indels and are mediated by ligase I/III 25, 26 . However, we looked in-depth at the Kell locus targeted in zygotes (Supplementary Fig. 8) , and saw no obvious signs of alternative NHEJ. This may be due to Scr7 inhibition of ligase III activity or to alternative NHEJ pathways being less efficient in zygotes. For cellbased experiments, the effect of alternative NHEJ pathways warrants further investigation because ligase III-dependent chromosome translocations occur more frequently in cancer cells 26 . Although in this study we used Scr7 to promote HDR frequency, we propose that other NHEJ inhibitors, for example, compounds that target DNA-dependent protein kinases, might also promote HDR. From a practical standpoint, we observe an improvement in the efficiency of precise genome editing by CRISPR-Cas9 in fertilized zygotes, which facilitates the generation of gene-targeted mice with insertions at multiple loci. The possibility of using Scr7 as a means of enhancing homology-directed repair was recently also mentioned in a review article 32 that was published while our manuscript was under review. Given that the molecular mechanisms involved in NHEJ and HDR are conserved across eukaryotes, the method may be applicable to nonmammalian species as well. Blastocysts, E10 embryos and newborn pups were prepared as in Figure 2 and Supplementary Figure 6 with Scr7. The genotypes of the samples were analyzed by insertionspecific primer genotyping and/or RFLP. The genotypes were confirmed by direct sequencing. Percentages of NHEJ and HDR were calculated by the number of the deletion and/or the insertion alleles against that of total alleles. *P < 0.05 (Igkc), ***P < 0.005 (Kell), comparing the frequency of deletion, insertion and wild-type alleles in the mouse cohort generated with or without NHEJ inhibitor (Scr7) treatment. Non-ins: non-insertion; BDF, B6D2F1.
npg l e t t e r s Figure 2 for the time course of the cell viability assay.
Zygote co-injections with NHEJ inhibitor. All animal procedures were performed according to US National Institutes of Health guidelines and approved by the Committee on Animal Care at MIT. Intracytoplasmic injection of fertilized zygotes was done as previously described 6 . Superovulated female B6D2F1 mice (7-8 weeks of age) were mated to B6D2F1 stud males, and fertilized zygotes were collected from oviducts. Cas9 mRNA (100 ng/µl), sgRNA (50 ng/µl) and template oligos (100 ng/µl) were mixed, and Scr7 (final concentration: 1 mM) were mixed and injected into zygotes at the pronuclear stage (24 h after administration of human chorionic gonadotropin). The injected zygotes were cultured in KSOM with fetal bovine serum at 37 °C and 6% CO 2 to the two-cell stage, and then were implanted into pseudopregnant female CD1-Elite mice.
Mouse and blastocyst genotyping. Mouse tails were lysed at 55 °C for 12 h using tail lysis buffer, and genomic DNA was purified from the lysates by isopropanol precipitation. Genomic DNA in proximity to the guide sequence of sgRNA was amplified by PCR using the primers listed in Supplementary  Table 2 and then gel purified. The purified PCR products were digested with MboI, and sequenced using the same forward and/or reverse primer. For blastocyst genotyping, Scr7-co-injected blastocysts were transferred to PCR tubes containing 5 µl of QuickExtract buffer (Epibio; no. QE09050). The samples were incubated at 65 °C for 6 min, and then at 98 °C for 2 min. PCR was done as described in "Cell-based genotyping" using an LPETG-specific primer, Kell-forward and Kell-reverse primers (Supplementary Table 3 ).
Designing CRISPR target sequence and prediction of off-target effects.
Guide sequences of sgRNA for CRISPR interference were designed as previously detailed 9 . The target sequence preceding the PAM motif was obtained from the exon region of the indicated genes. Potential off-target effects of guide sequence were predicted using NCBI Nucleotide BLAST. The guide sequences of sgRNAs used are shown in Supplementary Table 4 . The targeting templates for human TSG101 and Tap1 contain the 100-bp and 213-bp homology sequences on each side, respectively.
Cell-based genotyping. Cells were lysed at 55 °C for 2 h using tail lysis buffer (1% SDS, 100 mM NaCl, 50 mM Tris and 1 mM EDTA) containing proteinase K (Roche Diagnostics; no. 03115879001). Genomic DNA was purified from the lysates by isopropanol precipitation. Genomic DNA in the vicinity of the sgRNA target was amplified using the primers listed in Supplementary 
Construction of sgRNA vectors and plasmid donors.
The sgRNA template sequence for site-directed mutagenesis was designed as in Supplementary  Table 5 and was incorporated into the NheI/BamHI site of CMV promoterdeleted pCDH-EF1-Hygro (SBI; CD515B-1). The vectors for expressing sgRNA targeting human TSG101 and mouse Tap1 (pCDH-EF1-Hygro-hTSG101-sgRNA and pCDH-EF1-Hygro-mTap1-sgRNA) were constructed using the primers listed in Supplementary Table 6 for site-directed mutagenesis (GM Biosciences, Inc.; no. 7001). The stop cassette for hTSG101 and the Venus reporter gene for mTap1 were designed to be in the proximity of each guide sequence as shown in Figure 1b and Supplementary Table 4 . The targeting template for the hTSG101 locus and the mTap1 locus (Supplementary Table 7) were incorporated into pCDH-CMV-MCS-EF1-RFP (SBI; CD512B-1) and pCDH-EF1-Hygro (SBI; CD515B-1), respectively, using NheI and BamHI sites on the targeting templates and SpeI and BamHI sites on the vectors (Supplementary Table 7) .
Genotyping primers and targeting template design. TSG101. The targeting template contains 100 bp homology arms flanking the DSBs on both sides. The presence of the stop cassette in the TSG101 locus was analyzed using an internal forward primer specific for the stop cassette and an external reverse primer specific for a sequence outside of the flanking arm (Fig. 1b , primer set #1, reverse primer: 419 bp downstream of the PAM motif). The genomic region is targeted by external primers as an internal control (Fig. 1b , primer set #2, forward primer: 229 bp upstream of the PAM motif, reverse primer: identical to the reverse primer of set #1). The sequences of the primers and targeting templates are shown in Supplementary Tables 3 and 7 . Tap1: We prepared two constructs: pDonor0.2 as a template donor and pCtrl0.9 as a positive control for PCR. pDonor0.2 contains 213 bp flanking arms on either side of a Venus reporter gene to induce HDR in front of the PAM motif (GFP mutant Venus size: 813 bp); pCtrl0.9 has longer homology arms (Fig. 1d, bottom; length of upstream homology arm: 914 bp; length of downstream arm: 660 bp) and was used to provide a comparative PCR product of the Venus-inserted Tap1 locus in lanes 1 and 2 of Figure 1g . For primer sets to detect the insertion of the Venus gene and positive control plasmid, external primers were designed outside of the 213 bp homology arms of pDonor0.2. Primer set #1: a pair of external forward and reverse primers designed outside of the homology arms (forward primer: 258 bp upstream of the PAM motif; reverse primer: 252 bp downstream of the PAM motif), primer set #2: the forward primer from primer set #1 and a Venus-specific reverse primer, primer set #3: a Venus-specific forward primer and the external reverse primer from primer set #1. The sequences of primers and targeting templates are shown in Supplementary Tables 3 and 7 .
Igκ constant region. External primers were designed outside of the homology arms flanking the DSBs. Primer set #1: a sortase motif-specific forward primer and an external reverse primer targeting the Igκ constant region (Igkc) >250 bp downstream of the DSB; primer set #2: a pair of external forward and reverse primers targeting the genomic region >250 bp up-and downstream of the DSB.
Cell culture. MelJuSo and DC2.4 cells were grown in RPMI supplemented with 10% heat-inactivated FBS (IFS) at 37 °C and 5% CO 2 . A549 cells were cultured in DMEM supplemented with 10% IFS at 37 °C and 5% CO 2 .
Lentivirus generation. pCW-Cas9 (provided by D. Sabatini) 4 or pCDH-EF1-Hygro-sgRNA were co-transfected into HEK293T cells with the virus packaging vector, pMD2.G and psPAX2. After 48 h, supernatants were collected, and the virus was concentrated using PEG (SBI; no. LV810A-1) and dissolved in PBS.
Lentivirus transduction and selection for sgRNA stable Cas9-inducible cells. A549, MelJuSo and DC2.4 cells were infected with lentivirus expressing Cas9 cDNA and were cultured in puromycin-containing medium (Sigma-Aldrich; no. P9620) (A549: 1.5 µg/ml, MelJuSo: 2 µg/ml, DC2.4: 7 µg/ml). These Cas9-inducible cells were re-infected with lentivirus carrying sgRNA-coding DNA and were cultured in medium containing hygromycin B (Life Technologies no. 10687010) (A549: 100 µg/ml; MelJuSo: 100 µg/ml; DC2.4: 250 µg/ml).
sgRNA and Cas9 mRNA synthesis. Cas9 mRNA was prepared as described 6 . The T7 promoter-fused mKell-CT-or Igκ-CT-targeting guide sequence was added to 5′ of the sgRNA generic tail sequence by PCR amplification, using the pX330 vector (http://www.addgene.org/42230/) as a template. The primers used are listed in Supplementary Table 6 . The T7-sgRNA template PCR product for in vitro transcription (IVT) was gel-purified (Promega; PAA9282), and the purified PCR product was used as a template for IVT using MEGAshortscript T7 kit (Life Technologies; AM1354). Both Cas9 mRNA and sgRNAs were purified using MEGAclear kit (Life Technologies; AM1908) and eluted in RNase-free water.
Targeting single-stranded DNA template. The template single-stranded oligonucleotides for the insertion of LPETG into the Kell and Igkc region loci are listed in Supplementary Table 7. Quantification of band intensities. The area corresponding to the band of interest in Figure 1c , primer set no. 1 of upper panel, was selected in the Scr7-treated lanes (DMSO, 0.01-1 µM in Fig. 1c ) of A549 and MelJuSo cells, and a similar area with no obvious material was selected as background, and subtracted. Intensities measured for each lane were normalized by the intensities of the bands in the panel of primer set no. 2, (background subtracted for primer set no. 1). For DC2.4, total intensity of both inserted and unmodified bands are measured. Ratios of insertions over total (inserted and unmodified) were calculated, and then the fold change was calculated by comparing the ratio of insertions with Scr7 over that without Scr7. (Fig. 1b) , 650 bp of the TSG101 genomic region was amplified using primer set (no. 2) as in Figures 1c,d . The PCR products containing only the TSG101 genomic region were gel-purified. Using the purified 650-bp amplicon, we re-amplified ~200 bp of the TSG101 genomic region (a primer set: see Supplementary Table 3 , TSG101 partial P5FW/P7RV). Adaptor sequences and barcodes were then added using the primers listed in Supplementary Table 3 (MiSeq P5 universal FW, and MiSeq P7 RV barcode no. 1/no. 2).
Antibody
Quantification of indel frequency by chip-based capillary electrophoresis. The PCR products, containing the wild-type amplicon (318 bp), inserted amplicon (336 bp) and deleted amplicon (<318 bp), were loaded onto an Agilent 2100 BioAnalyzer. In the chromatography data obtained, the region of 313 bp to 323 bp, 288 bp to 313 bp or 326 bp to 346 bp was gated to observe the peak of wt ( = 318 bp), deletion (<318 bp) or insertion ( = 336 bp), respectively. Insertion (%) was calculated by determining the ratio of chromatographic intensity in the insertion region over the total intensity. Deletion (%) was calculated in a similar fashion. Indel (%) is the sum of deletion (%) and insertion (%).
Quantification of indel frequency by deep sequencing.
For deep sequencing, the prepared PCR products, containing the adaptors and barcodes, were run on Illumina MiSeq (150 × 150-paired end read). All reads from MiSeq were analyzed with Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index. shtml) 27 , then read counts of deletion and insertion at the TSG101 locus were extracted using wild-type and stop cassette-inserted TSG101 sequence, respectively. Statistically analyzed data were visualized with visualizing software, IGV (http://www.broadinstitute.org/igv/home) 28 . Southern blot analysis. Genomic DNA was separated on a 0.5% agarose gel after digesting with EcoRI restriction enzyme, transferred to a nylon membrane (Millipore; INYC00010) and hybridized with PCR-DIG (Roche Diagnostics; 11636090910)-labeled probes. The Kell-LPETG-targeted alleles were detected using anti-Dioxigenin-AP Fab fragment (Roche Diagnostics; 11093274910).
Sortase-mediated labeling of immunoglobulin light chains with biotin. Pentamutant Sortase A was expressed and purified as described 30 . Approximately 150 µl of serum from a wild-type mouse and from a mouse carrying Igκ-LPETG mutation was used for labeling. The reaction mixture was assembled as follows: 500 µM GGG-biotin, 5 µM sortase A and 4 µl serum in 50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl 2 . The reaction was incubated at 4 °C for 1 h. The reaction mixture was then adsorbed onto protein-G beads (Roche Diagnostics; no. 11719416001) to remove nonimmunoglobulin serum components as well as the enzyme. Bound materials were released by incubation with SDS sample buffer at 98 °C and analyzed by SDS-PAGE. To detect biotin-modified immunoglobulin light chains, avidin-HRP (Fisher Scientific; 45000765) was used following transfer to a polyvinylidene difluoride (PVDF) membrane (Supplementary Fig. 9 ).
Quantification of band intensities and calculation methods of fold changes.
Tsg101 experiments. The area corresponding to the band of interest in Figure 1c , primer set #1 of upper panel, was selected in the Scr7-treated lanes (DMSO, 0.01-1 µM in Fig. 1c ) of A549 and MelJuSo cells, and a similar area with no obvious material was selected as background, and subtracted. Intensities measured for each lane were normalized by the intensities of the bands in the panel of a primer set #2 (background subtracted for primer set #1). The HDR frequency fold change was calculated by determining the ratio of band intensities at the different concentrations of Scr7 (lanes 4-6 and lanes 10-12) over the intensities observed in the absence of Scr7 (lanes 3 and 9) .
Tap1 experiments. Total intensity of both inserted and unmodified bands was measured. Ratios of insertions over total (inserted and unmodified) were calculated. The fold change in HDR frequency was calculated by determining the ratio of band intensities in the presence of Scr7 (Fig. 1e, lanes 3-5) over the intensities observed in the absence of Scr7 (Fig. 1e, lanes 6-8) . For the panel of primer set #1, the ratio of the inserted band intensities (arrow) over total band intensities (arrow + arrowhead) was calculated, and then the fold changes were determined.
Statistical analysis.
Fisher's exact test in Prism software was used to calculate P values when comparing the number of insertions in blastocysts co-injected with or without NHEJ inhibitor treatment. Fisher's exact test in R software was used to evaluate the significance in comparing the frequency of deletions, insertions and wild-type alleles in the mouse cohort generated with or without NHEJ inhibitor treatment. An input example for Fisher's test in R software is below:
Kell
Wild type Deletion Insertion Scr7 (−) 11 9 8 Scr7 (+) 10 0 14
HDR-mediated targeting. To control the timing of Cas9-mediated DSBs, we used cell lines encoding a genomically integrated, doxycycline-inducible Cas9 cassette. Next, we transduced these cell lines using a lentiviral system to introduce a second construct that stably expresses sgRNAs targeting a specific gene of interest ( Supplementary Fig. 1a , stable cell preparation). We then confirmed reduced levels of TSG101 protein after Cas9 induction ( Supplementary  Fig. 1b) . To enable template-based HDR, these cells were transfected with an additional plasmid donor encoding the intended insert flanked by 5′-and 3′-end homology arms, and Cas9 was induced by the addition of doxycycline (Fig. 1a, stimulation of HDR) .
Cell viability upon Scr7 treatment. To assess potential toxicity of Scr7, we checked cell viability after exposure to different concentrations of Scr7 npg (Supplementary Fig. 2a-c) . Cas9-expressing sgRNA stable cells were transfected with the plasmid donor and treated with Scr7 and doxycycline. Cell viabilities were then checked by MTT assay. A549 cells were slightly more susceptible to toxic effects of Scr7 than MelJuSo cells (Supplementary Fig. 2b-c) , and an increased concentration (10 µM) of Scr7 had a more toxic effect on cell viabilities of both cell lines. At concentrations less than 10 µM, cells recovered after 3 days of Scr7 treatment. To maintain healthy cells capable of entering S/G2, which is necessary for HDR, we chose a range from 0 to 1 µM of Scr7.
Germline transmission. In the preceding experiments, mice were harvested at E10. The embryos appeared phenotypically normal, but we wanted to confirm that Scr7 does not adversely affect the health of older mice. We obtained live mice containing either stop codon-introduced Os9 or stop cassette-inserted sphingomyelin synthase 2 (ref. 31) mutations ( Supplementary Fig. 5a and Table 1 ), which were generated by the Scr7-based approach. For both mutant lines, the adult mice appear healthy (up to at least 4 months of age), and germline transmission occurred successfully, as we obtained pups carrying the stop codon at the targeted site of the Os9 locus from the heterozygous parental mice (Supplementary Fig. 5b ).
Effect on off-target by Scr7 treatment. Because off-target effects can occur in CRISPR-based generation of mutant mice 5 , we checked for off-target effects at the most likely sites for the Kell-targeting guide sequence. We determined that the sequence most similar to the Kell-targeting guide occurs in the Cytoglobin locus, which has 1 mismatch relative to the Kell guide sequence (Supplementary Fig. 7a ). We observed no off-target effects at the Cytoglobin locus in either Scr7-treated or untreated embryos (Supplementary Fig. 7b ), consistent with a previous report 5 .
Long indel analysis. A deficiency of ligase IV/XRCC4 induces A-NHEJ pathways, which can potentially introduce longer indels at a low frequency 25, 26 . We thus checked whether the Kell locus proximal to the DSB contained any longer indels (Supplementary Fig. 8 ). As the length of deletion patterns in Xrcc4-knockout cells was reported to be less than 1 kbp 26 , we used a different primer set that can amplify a larger region (1,142 bp) of the Kell locus to detect the possible occurrence of longer indels (Supplementary Fig. 8 ). We did not detect any longer indels, although indels larger than ~1.1 kb would not have been detected by our analysis. We also only observed homozygous mutant mice. This may be an artifact of the analysis, as one allele is often undetectable by PCR in genome-edited mice 4, 5 . To confirm whether the homozygous mutants analyzed in Figure 2d carried such hidden alleles, we performed Southern blot analysis ( Supplementary  Fig. 8c,d) . We observed the expected ~8-kbp band corresponding to the Kell locus (arrow) upon digestion with EcoRI in the genomic DNA of mutant embryos (no. 1 and no. 2), which were observed as homozygous mutant in Figure 2d . These bands are similar intensities to those of the wild-type embryo (no. 3), suggesting that these embryos do not lose a copy of the entire Kell gene by deletion.
